KR20240035483A - 알도스테론 합성효소 억제제를 사용하는 방법 - Google Patents

알도스테론 합성효소 억제제를 사용하는 방법 Download PDF

Info

Publication number
KR20240035483A
KR20240035483A KR1020247002601A KR20247002601A KR20240035483A KR 20240035483 A KR20240035483 A KR 20240035483A KR 1020247002601 A KR1020247002601 A KR 1020247002601A KR 20247002601 A KR20247002601 A KR 20247002601A KR 20240035483 A KR20240035483 A KR 20240035483A
Authority
KR
South Korea
Prior art keywords
compound
dose
study
treatment
visit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247002601A
Other languages
English (en)
Korean (ko)
Inventor
메리 본드
브라이언 머피
캐서린 피어스
Original Assignee
신코 파마, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 신코 파마, 인크. filed Critical 신코 파마, 인크.
Publication of KR20240035483A publication Critical patent/KR20240035483A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020247002601A 2021-06-24 2022-06-24 알도스테론 합성효소 억제제를 사용하는 방법 Pending KR20240035483A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163214521P 2021-06-24 2021-06-24
US63/214,521 2021-06-24
US202163290364P 2021-12-16 2021-12-16
US63/290,364 2021-12-16
PCT/US2022/073148 WO2022272300A1 (en) 2021-06-24 2022-06-24 Methods of using aldosterone synthase inhibitors

Publications (1)

Publication Number Publication Date
KR20240035483A true KR20240035483A (ko) 2024-03-15

Family

ID=84545863

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247002601A Pending KR20240035483A (ko) 2021-06-24 2022-06-24 알도스테론 합성효소 억제제를 사용하는 방법

Country Status (10)

Country Link
US (1) US20240277698A1 (https=)
EP (1) EP4358959A4 (https=)
JP (1) JP2024523559A (https=)
KR (1) KR20240035483A (https=)
AU (2) AU2022299103B2 (https=)
BR (1) BR112023027025A2 (https=)
CA (1) CA3223211A1 (https=)
IL (1) IL309428A (https=)
MX (1) MX2023015121A (https=)
WO (1) WO2022272300A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024310688A1 (en) * 2023-06-29 2026-01-29 AstraZeneca Ireland Limited Crystal form of baxdrostat, and preparation method therefor and use thereof
CN121712504A (zh) * 2023-07-27 2026-03-20 矿物疗法公司 用洛伦司他及两种或更多种降压药的组合治疗高血压的方法
TW202525278A (zh) * 2023-12-15 2025-07-01 愛爾蘭商阿斯特捷利康愛爾蘭有限公司 治療慢性腎病及高血壓之方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4777896A (en) * 1995-02-10 1996-08-27 G.D. Searle & Co. Use of low dose amount of spironolactone for treatment of cardiovascular disease
US20070196510A1 (en) * 2006-02-17 2007-08-23 Gerber Michael J Method for treating resistant hypertension
US9353081B2 (en) * 2011-09-23 2016-05-31 Hoffmann-La Roche Inc. Bicyclic dihydroquinoline-2-one derivatives

Also Published As

Publication number Publication date
EP4358959A1 (en) 2024-05-01
WO2022272300A1 (en) 2022-12-29
AU2022299103A1 (en) 2024-01-25
IL309428A (en) 2024-02-01
AU2022299103B2 (en) 2025-12-18
US20240277698A1 (en) 2024-08-22
AU2026201954A1 (en) 2026-04-02
JP2024523559A (ja) 2024-06-28
EP4358959A4 (en) 2025-05-14
CA3223211A1 (en) 2022-12-29
MX2023015121A (es) 2024-04-16
BR112023027025A2 (pt) 2024-03-12

Similar Documents

Publication Publication Date Title
KR20240035483A (ko) 알도스테론 합성효소 억제제를 사용하는 방법
CA2879548C (en) Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
JP2010518169A (ja) 心血管疾患の処置のためのラノラジンの使用
JP7620758B2 (ja) 肺動脈性肺高血圧症の治療方法
JP7402907B2 (ja) ネコの全身性疾患の予防又は治療用アンジオテンシンｉｉ受容体拮抗薬
US20260041679A1 (en) Method of treating hypertension with the aldosterone synthase inhibitor baxdrostat
WO2022182982A1 (en) Methods for treating c-kit kinase mediated diseases and disorders using a selective c-kit kinase inhibitor
JP2011511844A (ja) 心血管疾患の処置のためのラノラジンの使用
WO2022115576A2 (en) Treatment of raynaud's disease
EP2837380B1 (en) Lercanidipine hydrochloride and losartan potassium compound preparation and preparation method thereof
CN117545482A (zh) 使用醛固酮合酶抑制剂的方法
WO2025038481A1 (en) Vepdegestrant dosage regimen in cyp3a-inducer treatment in cancer
CN115666564B (zh) 在单层片剂中包括氨氯地平、氯沙坦和氯噻酮的预防或治疗心血管系统疾病的药学上组合制剂
US20250367137A1 (en) Phloroglucinol Formulations And Methods Of Use
US20250222003A1 (en) Pharmaceutical composition for treating solid tumors
WO2008134047A1 (en) Methods of treating hypertension
EP4574148A1 (en) Fixed combination of telmisartan, amlodipine and indapamide for the treatment of hypertension
HK40082224B (zh) 在单层片剂中包括氨氯地平、氯沙坦和氯噻酮的预防或治疗心血管系统疾病的药学上组合制剂
TW202214238A (zh) 在單層片劑中包括氨氯地平、氯沙坦和氯噻酮的預防或治療心血管系統疾病的藥學上組合製劑
HK40082224A (en) Complex pharmaceutical preparation, for preventing or treating cardiovascular disease, comprising amlodipine, losartan and chlorthalidone in single-layer tablet
HK40087811A (zh) 用於治疗具有严重肝损伤的受试者的非转移性去势抵抗性前列腺癌的雄激素受体抑制剂

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000